ist, and they act synergistically in terms of increased risk (3) .
Antihypertensive drugs affect the lipid profile in different ways, and they can be broadly divided into three groups: lipid-hostile (12-14) (β-blockers and thiazide diuretics); lipid-neutral (12,14,15) (angiotensin converting enzyme inhibitors [ACE-Is], calcium channel blockers [Cablockers] , and angiotensin II receptor blockers [ARBs]); and lipid-friendly (14,16) (α-blockers). In addition, antihypertensive drugs may exert beneficial or unfavorable effects on some of the "emerging" risk factors, such as Fib (17, 18) .
We investigated the influence of hypertension, and its treatment, on circulating lipid, and Fib concentrations in patients with essential hypertension attending this university hospital-based outpatient hypertension clinic, in Crete, Greece.
MATERIALS AND METHODS

Patient Selection and Study Design
The records of all patients referred to the Hypertension Clinic at this hospital were screened retrospectively. The sampling period extended from January 2000 to June 2003.
Patients were included in the study if they were either known hypertensives receiving antihypertensive treatment or they had a diastolic blood pressure (DBP) ≥ 90 mm Hg and/or systolic blood pressure (SBP) ≥ 140 mm Hg on two subsequent visits.
To create a more homogeneous patient group, the following exclusion criteria were applied: 01. Abnormal results from liver function tests. Reference ranges were as follows: aspartate aminotransferase (AST) = 5 to 40 U/L; alanine aminotransferase (ALT) = 5 to 40 U/L; gammaglutamyl transferase (GGT) = 10 to 50 U/L; alkaline phosphatase (ALP) = 35 to 130 U/L (patients with values of AST, ALT, or GGT up to three times the reference range were not excluded if they had a normal-appearing liver ultrasound and negative serologic tests for hepatitis B and C, as they were assumed to suffer from nonalcoholic fatty liver disease). Alcoholic intake limits are defined in (4), below.
02. Abnormal renal function. Reference ranges were: creatinine (Cr) = 0.5 to 1.5 mg/dL (44 to 133 µmol/L).
03. Abnormal results from thyroid function tests. Reference ranges were: thyrotropin (TSH) = 0.16-4.7 U/L; we did not exclude patients suffering from hypothyroidism if they were receiving long-term (1 year) thyroxine replacement and had normal TSH values.
04. Declared or determined history of alcohol or other drug abuse. For alcohol, the limits were set as 21 units(U)/week for men and 14 U/week for women.
05. Current psychiatric treatment. 06. Chronic inflammatory disease (e.g., rheumatoid arthritis, Crohn's disease, ulcerative colitis, collagen diseases) or cancer. This is because Fib is an acute phase protein (6).
07. Recent (3 months) major cardiovascular or other illness, angioplasty, or surgery.
08. Treatment with hypolipidemic agents, as they affect Fib concentrations (19) (20) (21) (22) .
09. Treatment with drugs: these include retinoic acid derivatives, tamoxifen, androgens, estrogens, progestins, fish oils, or cyclosporin, as these drugs may influence lipid and possibly Fib levels (23) .
10. Current or recent (4 months) pregnancy.
DEFINITIONS
Patients were considered as having established vascular disease if they had at least one of the following: previous myocardial infarction; stenosis (>70%) of at least one coronary artery on angiography; previous coronary artery bypass graft or angioplasty; positive stress ECG or echocardiogram; previous stroke; or previous transient ischemic attack.
Diabetics were considered those who either had fasting serum glucose (Glu) levels >126 mg/dL (>7.0 mmol/L) in two different specimens or were treated with oral antidiabetic agents or insulin.
Smoking Status
Nonsmokers were defined as those who have never smoked or who quit 6 or more months before sampling.
CLINICAL AND LABORATORY INVESTIGATIONS
Collection of Samples
All samples were collected in the morning after fasting overnight for 12 h with only water allowed.
Lipid Profile
The (23) .
Fibrinogen
Samples were collected in trisodium citrate (1 mL 3.8% trisodium citrate + 9 mL blood) and measured by the Clauss method (clotting activity) using an autoanalyzer (ACL 300 Research; IL Labs, Warrington, England), as previously described (23) .
Liver and Renal Function Profiles and Serum Glu Concentration
These were all determined by standard methods in routine use. Our department of Clinical Chemistry participates in two quality assurance assessment programs (Bio-Rad and Hellenic EQAS).
Antihypertensive Drugs
Antihypertensive drugs were classified as follows: 1) 'lipid-hostile'-β-blockers and thiazide diuretics (mainly hydrochlorothiazide); 2) 'lipidneutral'-ACE-I; Ca-blockers; ARBs; or 3) 'lipidfriendly'-α-blockers.
When a patient was taking a combination of a lipid-hostile and a lipid-neutral drug, he or she was considered in the lipid-hostile group. There were no patients receiving a lipid-friendly antihypertensive drug.
Statistical Analysis and Presentation of Results
Values are expressed as mean ± SD. All p values are two-tailed. We tested by one-way ANOVA if there was any significant difference among the three groups of patients (untreated hypertensives, those taking 'lipid-hostile,' and those taking 'lipid-neutral' drugs). Between-group results were assessed by t-test. Frequency analysis was by χ 2 test, with Yates' correction.
RESULTS
Patient Characteristics
We examined the records of 353 patients with essential hypertension. Their median age was 60 (range: 18-85) years old. There were 131 (37.1%) men ( Table 1 ). The patients were divided into three groups according to their antihypertensive treatment: 117 patients (33.1%) were taking 'lipid hostile' agents; 74 (21.0%) were taking 'lipid neutral' drugs. No patients were taking 'lipid friendly' drugs, and 162 patients (45.9%) were not taking any antihypertensive treatment.
The two groups taking antihypertensive (either 'lipid-neutral' or 'lipid-hostile') drugs included patients of significantly greater age, fewer men, and fewer smokers when compared with the untreated ones. In addition, there were significantly more diabetics and/or patients with vascular disease in the 'lipid-hostile' group than in the other two groups. Table 2) .
Untreated hypertensives had significantly lower serum HDL levels when compared with those taking 'lipid-neutral' antihypertensives (48 ± 11 vs. 52 ± 15 mg/dL, p <0.05). There were no significant differences in the other lipid variables.
Serum glucose (Glu) levels were significantly elevated in the group of patients taking 'lipidhostile' treatment, when compared with untreated ones (117 ± 53 vs. 104 ± 35 mg/dL, p <0.05). There were no significant differences in serum creatinine (Cr) concentration among the three groups of patients.
Fib Concentrations and Lipid Profile in Hypertensives Divided into Three Groups According to Their Antihypertensive Treatment After Smokers and Patients with DM and/or Vascular Disease Were Excluded (n=220)
It is known that smoking, diabetes mellitus (DM), and vascular disease affect both plasma Fib levels (5-7,24,25) and lipid profile (2, 26, 27) . We excluded smokers and patients with vascular disease or diabetes from our original population. The new groups were more homogeneous as they had no significant difference either in age or in sex distribution ( Table 3) . As we mentioned in Methods, no patient was receiving hypolipidemic treatment.
Patients who were taking 'lipid-hostile' antihypertensive drugs had significantly higher plasma Fib concentrations when compared with those taking 'lipid-neutral' antihypertensives or those who were not receiving any antihypertensive treatment (345 ± 76 vs. 313 ± 67 mg/dL, p < 0.05 and 345 ± 76 vs. 318 ± 67 mg/dL, p < 0.05, respectively) ( Table 4) .
In addition, patients on 'lipid-neutral' treatment had significant higher serum HDL levels when compared with both those taking 'lipidhostile' antihypertensives (55 ± 11 vs. 51 ± 10 mg/dL, p <0.05) and untreated ones (55 ± 11 vs. 49 ± 10 mg/dL, p <0.01). There were no significant differences in the other lipid variables (Table 4) .
There were no significant differences in serum Glu and Cr concentration among the three groups of patients (Table 4) .
DISCUSSION
Patients who were taking 'lipid-hostile' antihypertensive drugs had significantly higher plasma Fib concentrations when compared with those taking 'lipid-neutral' or those who were not receiving any antihypertensive treatment. This finding remained statistically significant even after smokers, diabetics, and patients with vascular disease were excluded. These more homogeneous groups had no significant difference either in age or in sex distribution (Table 3) . Therefore, our findings were not attributable to established factors that influence plasma Fib levels, such as smoking (7,26), DM (7), vascular disease (7,27,28), sex (7,29), and age (30, 31) .
Patients with hypertension in many clinical studies (4,32-34) have increased plasma Fib concentrations. Our results suggest that antihypertensive drugs influence the circulating levels of Fib. ACE-Is (35) (e.g., perindopril (36,37), enalapril (38), lisinopril (17) , cilazapril (37,39)) decrease plasma Fib levels. There are studies showing that some ARBs like valsartan (40) and irbesartan (41) also decrease plasma Fib levels. However, losartan did not significantly affect Fib concentrations (42, 43) .
Ca-blockers (nifedipine (44, 45) , felodipine (37,46), amlodipine (17, 47) , diltiazem (48) , and verapamil (12)) did not alter plasma Fib concentrations. Only isradipine, in a single study, decreased the elevated Fib concentration compared with placebo (49) . In contrast, Koenig et al (46) showed in 28 mild to moderate hypertensives that Fib plasma levels were significantly elevated when their treatment switched from felodipine to hydrochlorothiazide. Chlorthalidone (25 mg/day) also reversed the beneficial effect of cilazapril (5 mg/day) monotherapy on Fib concentration (39). Because Fib is an independent cardiovascular risk factor (6,7), the potentially harmful or beneficial effects of antihypertensive agents should be considered in the management of overall cardiovascular risk.
In a previous study (23) we showed a similar effect of antihypertensive treatment on plasma Fib levels. However, there were several differences in the populations of these two studies. First, the former study was run in London, where patients have a typical Western diet, whereas the present study was carried out in Crete (Greece), where a Mediterranean diet is consumed. Second, all hypertensives in the first study had dyslipidemia, whereas in the present study some but not all of our patients had dyslipidemia. Finally, the percentage of hypertensives with vascular disease in the first study was high (54%), whereas we excluded these patients from one of our subgroup analyses. From these two studies, we may propose that 'lipid-hostile' hypertensive drugs exert an unfavorable effect on plasma Fib levels. Furthermore, this effect is likely to be independent of dietary patterns, lipid levels, and the presence/absence of vascular disease.
In a recent study (55) , 6 months of intensified cardiovascular risk management resulted in significant improvements in indices of endothelial, platelet, and rheologic function in hypertensives, independently of the fall in blood pressure. Given the essential role of interactions between the endothelium and circulating blood components in the pathogenesis of hypertensive complications, this may be of importance in preventing adverse cardiovascular outcomes.
In addition, hypertensives on 'lipid-neutral' treatment had significantly higher serum HDL levels when compared with either untreated patients or those taking 'lipid-hostile' drugs. This difference was not attributable to established factors that influence serum HDL levels, such as smoking (26) , DM (56), or vascular disease (2), as we excluded these patients from our analyses (Table 4) .
Hypertension is associated with increased insulin resistance, which leads to low serum HDL levels (57, 58) . ACE-Is and ARBs may raise serum HDL concentration by increasing insulin sensitivity (14, 17, 59, 60) . Blood pressure reduction with Ca-blockers also improves insulin sensitivity in hypertensive patients (61) . On the other hand, many studies have shown that diuretics and β-blockers decrease HDL levels (50, (62) (63) (64) and insulin sensitivity (65, 66) .
The number (and variable doses) of different antihypertensive drugs used is a limitation of this retrospective study. However, the size of the study population is large enough to provide statistical power. A large prospective study could confirm our results.
In the light of new evidence showing differences in the incidence of ischemic heart disease (67) and stroke (68) (69) (70) between antihypertensives, our findings suggest that it is relevant to assess the lipid variables as well as Fib levels (and perhaps other hemostatic variables) in trials evaluating antihypertensive drugs. Although lipid levels are often documented, recent key hypertension trials do not report Fib levels.
In 
